TREATMENT OF PATIENTS WITH GASTRIC CANCER LIVER METASTASES

*F. M. Djuraev, S. S. Khudoyarov and M. D. Djuraev

ABSTRACT

Relevance of the study Despite of steady decline in the incidence of gastric cancer (GC), for many countries, this pathology remains one of the most important medical and socio-economic problems.[1,2,3,5] Analysis of mortality data in 24 economically developed countries showed that GC accounts for 50% of gastrointestinal tumors.[6,7,11] According to WHO and American statistics, the world annually diagnoses about 1 million new cases of gastric cancer, yielding only to lung cancer. In Russia, GC is the second most common diagnosed - every year recorded 48,8 thousand of new cases, which is just over 11% of all cancers. 60-90% of patients are diagnosed at stage III - IV disease.[4,5,6,8] According to RSSPMCO&R Ministry of health of the Republic of Uzbekistan in 2018 in the Republic, GC was diagnosed in 1950 patients, in the structure of all malignancies it takes the 2nd place, behind breast cancer. The problem of treatment of widespread and disseminated GC becomes particularly relevant in this situation. Unfortunately, despite the progress made in the diagnostics, surgical treatment, adjuvant chemotherapy, the prognosis for advanced GC is still unsatisfactory. If in the locally advanced process (T4N2M0), the majority of surgeons still adhere to active tactics, the detection of metastatic liver damage, peritoneal dissemination or metastases to paraaortic lymph nodes often forces them to abandon the attempt to perform resection or gastrectomy.[7,9,10,12] In this regard, the aim of this study is to improve the effectiveness of treatment of patients with liver metastases using surgical and combined methods of treatment.

Keywords: .